BerandaLCTX • NYSEAMERICAN
add
Lineage Cell Therapeutics Inc
$1,63
Setelah Jam Perdagangan Normal:(1,22%)+0,020
$1,65
Tutup: 15 Apr, 18.22.59 GMT-4 · USD · NYSEAMERICAN · Pernyataan Penyangkalan
Tutup sebelumnya
$1,59
Rentang hari
$1,58 - $1,69
Rentang tahun
$0,40 - $2,09
Kapitalisasi pasar
406,01Â jt USD
Volume Rata-Rata
1,16Â jt
Rasio P/E
-
Hasil dividen
-
Dalam berita
Keuangan
Laporan Laba Rugi
Pendapatan
Penghasilan bersih
| (USD) | Des 2025info | Perubahan Y/Y |
|---|---|---|
Pendapatan | 6,61Â jt | 130,40% |
Biaya operasional | -4,11Â jt | 1,53% |
Penghasilan bersih | 851,00Â rb | 126,00% |
Margin laba bersih | 12,88 | 111,29% |
Penghasilan per saham | 0,00 | 100,00% |
EBITDA | -6,36Â jt | -28,29% |
Tarif pajak efektif | 120,33% | — |
Neraca
Total aset
Total liabilitas
| (USD) | Des 2025info | Perubahan Y/Y |
|---|---|---|
Investasi tunai jangka pdk | 55,78Â jt | 16,68% |
Total aset | 112,58Â jt | -0,56% |
Total liabilitas | 69,24Â jt | 91,23% |
Total ekuitas | 43,35 jt | — |
Saham yang beredar | 249,09 jt | — |
Harga terhadap nilai buku | 8,83 | — |
Tingkat pengembalian aset | -16,19% | — |
Tingkat pengembalian modal | -47,32% | — |
Arus Kas
Perubahan kas bersih
| (USD) | Des 2025info | Perubahan Y/Y |
|---|---|---|
Penghasilan bersih | 851,00Â rb | 126,00% |
Kas dari operasi | -4,88Â jt | 23,13% |
Kas dari investasi | -15,33Â jt | -681,94% |
Kas dari pembiayaan | 20,38Â jt | -6,23% |
Perubahan kas bersih | 347,00Â rb | -98,08% |
Arus kas bebas | -2,61Â jt | 25,32% |
Tentang
Lineage Cell Therapeutics, Inc. is a clinical-stage biotechnology company developing novel cell therapies for unmet medical needs. Lineage’s programs are based on its robust proprietary cell-based therapy platform and associated in-house development and manufacturing capabilities. With this platform, Lineage develops and manufactures specialized, terminally differentiated human cells from its pluripotent and progenitor cell starting materials. These differentiated cells are developed to either replace or support cells that are dysfunctional or absent due to degenerative disease or traumatic injury or administered as a means of helping the body mount an effective immune response to cancer. Wikipedia
Didirikan
1990
Situs
Karyawan
75